Cargando…

A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study

BACKGROUND: While the cardioprotective benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors have been established in patients with cardiovascular disease (CVD), their advantages over other anti-diabetic drugs at earlier stages remain unclear. We compared the cardioprotective effects of empa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hiruma, Shigenori, Shigiyama, Fumika, Hisatake, Shinji, Mizumura, Sunao, Shiraga, Nobuyuki, Hori, Masaaki, Ikeda, Takanori, Hirose, Takahisa, Kumashiro, Naoki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852076/ https://www.ncbi.nlm.nih.gov/pubmed/33530982 http://dx.doi.org/10.1186/s12933-021-01228-3

Ejemplares similares

Rationale, Design for the ASSET Study: A Prospective Randomized Study Comparing Empagliflozin’s Effect to Sitagliptin on Cardiac Fat Accumulation/Function in Patients with Type 2 Diabetes
por: Shigiyama, Fumika, et al.
Publicado: (2019)

Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study
por: Shigiyama, Fumika, et al.
Publicado: (2018)

Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well‐controlled type 2 diabetes: A 24‐week randomized controlled trial
por: Ando, Yasuyo, et al.
Publicado: (2021)

Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
por: Fuchigami, Ayako, et al.
Publicado: (2020)

Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
por: Shigiyama, Fumika, et al.
Publicado: (2017)

Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function
por: Shigiyama, Fumika, et al.
Publicado: (2016)

Characteristics of hepatic insulin‐sensitive nonalcoholic fatty liver disease
por: Shigiyama, Fumika, et al.
Publicado: (2017)

Empagliflozin: Novel antidiabetes and pro-cardiac drug
por: Raut, Monish S, et al.
Publicado: (2017)

Sustained fasting glucose oxidation and postprandial lipid oxidation associated with reduced insulin dose in type 2 diabetes with sodium–glucose cotransporter 2 inhibitor: A randomized, open‐label, prospective study
por: Kanazawa, Ken, et al.
Publicado: (2019)

A Real-World, Prospective, Non-interventional Study of Adults with T2D Switching to IDegAsp from Glargine U100 or U300 in Japan
por: Shigiyama, Fumika, et al.
Publicado: (2021)

Effect of high-fat diet and empagliflozin on cardiac proteins in mice
por: Pan, Xiaoyu, et al.
Publicado: (2022)

Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells
por: Chen, Sha, et al.
Publicado: (2023)

Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes
por: Madonna, Rosalinda, et al.
Publicado: (2020)

Cardioprotective Effect of Quercetin and Sitagliptin in Doxorubicin-Induced Cardiac Toxicity in Rats
por: Aziz, Tavga Ahmed
Publicado: (2021)

Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats
por: Trang, Nguyen Ngoc, et al.
Publicado: (2021)

Adjunctive Sitagliptin Therapy in Postoperative Cardiac Surgery Patients: A Pilot Study
por: Brackbill, Marcia L., et al.
Publicado: (2012)

Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload
por: Nakao, Masaaki, et al.
Publicado: (2021)

Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin
por: Juni, Rio P., et al.
Publicado: (2019)

Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death
por: Hu, Zhaoyang, et al.
Publicado: (2021)

Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin
por: Puar, Pankaj, et al.
Publicado: (2023)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
por: Htoo, Phyo T., et al.
Publicado: (2022)

Association of Fine Particulate Matter Exposure With Bystander-Witnessed Out-of-Hospital Cardiac Arrest of Cardiac Origin in Japan
por: Kojima, Sunao, et al.
Publicado: (2020)

Empagliflozin improves chronic hypercortisolism-induced abnormal myocardial structure and cardiac function in mice
por: Zhang, Qing-Qing, et al.
Publicado: (2020)

Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis
por: Zou, Rongjun, et al.
Publicado: (2022)

Empagliflozin Inhibits Cardiac Late Sodium Current by Ca/Calmodulin-Dependent Kinase II
por: Mustroph, Julian, et al.
Publicado: (2022)

Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling
por: Verma, Raj, et al.
Publicado: (2023)

Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study
por: Ahmed, Ibrar, et al.
Publicado: (2022)

CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece
por: Ghetti, Gianni, et al.
Publicado: (2023)

Remote Cardiac Rhythm Monitoring in the Era of Smart Wearables: Present Assets and Future Perspectives
por: Xintarakou, Anastasia, et al.
Publicado: (2022)

Sodium–Glucose Co-Transporter 2 Inhibition With Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism
por: Tan, Yunke, et al.
Publicado: (2021)

Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome
por: Kusaka, Hiroaki, et al.
Publicado: (2016)

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
por: Byrne, Nikole J., et al.
Publicado: (2017)

Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes
por: Ng, Kwong-Man, et al.
Publicado: (2018)

Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions
por: Liang, Bo, et al.
Publicado: (2020)

Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus
por: Hsu, Jung-Chi, et al.
Publicado: (2019)

The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats
por: Daud, Elias, et al.
Publicado: (2021)

Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db/db mice
por: Tu, Yimin, et al.
Publicado: (2022)

Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis
por: Chung, Cheng-Chih, et al.
Publicado: (2023)

Randomized Clinical Trial on Efficacy of Empagliflozin Versus Sitagliptin, In Addition to Metformin in Type 2 Diabetic Patients
por: Mubashir, Muaz, et al.
Publicado: (2022)

Evaluation of lung perfusion by using lung perfusion SPECT and lung CT with breathing synchronization software
por: Hashimoto, Hidenobu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7htmdf7vi9m3u417dr3v40npe0